RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9700
+0.0263 (2.79%)
At close: Jun 29, 2026, 4:00 PM EDT
0.9749
+0.0049 (0.51%)
Pre-market: Jun 30, 2026, 5:24 AM EDT
RenovoRx Revenue
RenovoRx had revenue of $563.00K in the quarter ending March 31, 2026, with 185.79% growth. This brings the company's revenue in the last twelve months to $1.49M, up 520.42% year-over-year. In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth.
Revenue (ttm)
$1.49M
Revenue Growth
+520.42%
P/S Ratio
29.38
Revenue / Employee
$87,588
Employees
17
Market Cap
43.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 22.33M |
| Radiopharm Theranostics | 10.86M |
| Apollomics | 8.84M |
| CervoMed | 2.09M |
| Hyperion DeFi | 1.04M |
| ABVC BioPharma | 797.92K |
RNXT News
- 6 days ago - RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Transcripts
- 15 days ago - RenovoRx Slides: Investor presentation - Filings
- 18 days ago - RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 25 days ago - RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - GlobeNewsWire
- 4 weeks ago - RenovoRx announces FDA Orphan Drug Designation for oxaliplatin - TheFly
- 4 weeks ago - RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - RenovoRx announces pharmacokinetic data using TAMP platform - TheFly
- 4 weeks ago - RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire